Browse studies

Find your next paid study

6 recruiting studies matching your filters

A Phase 2 Open-label Basket Study to Evaluate the Efficacy and Safety of Orally Administered Reversible Tyrosine Kinase Inhibitor BAY 2927088 in Participants With Metastatic or Unresectable Solid Tumors With HER2-activating Mutations

Researchers are looking for a better way to treat people who have solid tumors with HER2-activating mutations. Before a treatment can be approved for people to…

Advanced Solid TumorsHER2 Mutation

A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-10203 in Subjects With Advanced Solid Tumors (The BREAKER-101 Study)

First in human study to evaluate the safety, tolerability, and pharmacokinetics (PK) of BBO-10203, a PI3Kα:RAS breaker, alone and in combination with other ant…

Solid Tumor, AdultMetastatic Breast CancerAdvanced Breast Cancer+8 more

Estimated

~$10 – $8,750

TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)NCT06625775

Phase 1

PRE-Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis: A Phase I/II Platform Trial

PRE-ISPY Phase I/II (I-SPY-P1) is an open-label, multisite platform study with multiple ongoing drug regimen arms added by protocol amendment which is designed…

HER2-positive Breast CancerMetastatic CancerMetastatic Breast Cancer+29 more

Estimated

~$10 – $7,500

Phase 3

A Phase 3 Open-label, Randomized, Active-controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Orally Administered BAY 2927088 Compared With Standard of Care as a First-line Therapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With HER2-activating Mutations

Researchers are looking for a better way to treat people who have advanced non-small cell lung cancer (NSCLC) with specific genetic changes called human epider…

Advanced Non-small Cell Lung Cancer, HER2 Mutation

A Phase 1/1b Study of IAM1363 in Participants With Advanced Cancers Harboring HER2 Alterations

This is a Phase 1/1b open-label, multi-center dose escalation and dose optimization study designed to evaluate the safety and preliminary efficacy of IAM1363 i…

HER2 Mutation-Related TumorsHER2HER2-positive Breast Cancer+10 more

Estimated

~$10 – $8,750

Iambic Therapeutics, IncNCT06253871

Phase 1

An Open Label, First-in-human Study of BAY 2927088 in Participants With Advanced Non-small Cell Lung Cancer (NSCLC) Harboring an EGFR and/or HER2 Mutation

Researchers are looking for a better way to treat people who have advanced non-small cell lung cancer (NSCLC), a group of lung cancers that have spread to near…

Advanced Non-small Cell Lung CancerEGFR MutationHER2 Mutation

Estimated

~$10 – $7,500

BayerNCT05099172